GPT-Rosalind vs Claude Opus 5: A life-sciences specialist against a generalist flagship

The September 11, 2026 decision to take GPT-Rosalind — Open​AI's purpose-built life-sciences reasoning model — out of research preview is the first real chance to compare it head-to-head against the generalist frontier, and the natural opponent is Claude Opus 5, Anthrop​ic's flagship for demanding reasoning, coding, and long-horizon agentic work. GPT-Rosalind ships through Open​AI's trusted-access program with published pricing effective October 5, 2026, while Claude Opus 5 has been generally available since July 24, 2026 at $5.00/$25.00 per 1M tokens. Both are frontier models, but they were built for different jobs: Rosalind for drug discovery, genomics, and experimental planning; Opus 5 for the whole spectrum of enterprise reasoning. The question is whether a specialist's edge in biology justifies giving up a generalist's breadth.

Why this matchup exists now

For five months GPT-Rosalind existed only behind a U.S.-only trusted-access gate for a handful of named partners — Amgen, Moderna, the Allen Institute, Thermo Fisher Scientific. On September 11, 2026 O​penAI announced the model is coming out of research preview and is available globally to eligible organizations through the trusted-access program, with billing at $5.00 per 1M input tokens, $0.50 cached input, and $25.00 per 1M output tokens beginning October 5. The pricing effectively matches Claude Opus 5's $5.00/$25.00, which makes the comparison unusually clean: two frontier models at identical token prices, one specialized, one general.

Rosalind is named after Rosalind Franklin, whose X-ray diffraction work revealed the structure of DNA. The model itself, per O​penAI, is built for reasoning over molecules, proteins, genes, pathways, and disease-relevant biology, and for multi-step workflows like literature review, sequence-to-function interpretation, experimental planning, and data analysis. It is the first release in a life-sciences model series, with an open-source Life Sciences Research Plugin for Codex that connects it to more than 50 scientific tools and data sources.

The scoreboard

The honest first observation is that there is no apples-to-apples public benchmark comparing these two models. GPT-Rosalind's headline numbers are vendor- and partner-reported evaluations on domain tasks; Claude Opus 5 has independent scores from Artificial Analysis but no published biology-domain eval at this depth. So the scoreboard below separates the two kinds of evidence explicitly.

• Price — GPT-Rosalind $5.00 / $25.00 per 1M tokens (cached input $0.50), effective Oct 5, 2026. Claude Opus 5 $5.00 / $25.00 per 1M tokens (cache read $0.50, cache write $10.00). Identical headline rates.

• Access — GPT-Rosalind: trusted-access application, qualification review, US-first but now global to eligible organizations. Claude Opus 5: open API access to any account.

• AA Intelligence Index — Claude Opus 5: 50.7, #4 of 141. GPT-Rosalind: not tracked (specialized models don't appear on the general leaderboard).

• AA Coding — Claude Opus 5: 78.0, #2 of 138. GPT-Rosalind: n/a — its domain is wet-lab planning, not software engineering.

• Domain evals — GPT-Rosalind: BixBench leading (vendor-reported), 6 of 11 LABBench2 tasks above GPT-5.4 (vendor-reported), +53.7% performance-per-token on GeneBench (vendor), +18.0% on MedChemBench, +19.6% on LabWorkBench, +4.42% on LifeSci Bench (all O​penAI-reported). Claude Opus 5: no comparable published life-sciences suite.

• Context window — Both 1M tokens. Claude Opus 5 supports text, image, and file input with text output; GPT-Rosalind handles scientific file inputs through ChatGPT, Codex, and the API.

• Reasoning mode — Claude Opus 5 offers adaptive reasoning (auto, low-to-high). GPT-Rosalind is a reasoning model with tool use at its core, plus a reasoning_effort-style control in the API.

What Rosalind's numbers actually mean

The most-quoted Rosalind result comes from Dyno Therapeutics: on an unpublished RNA-sequence prediction task, best-of-ten generations exceeded the 95th percentile of 57 human AI-bio experts for prediction, and roughly the 84th percentile for sequence generation. That is a partner evaluation on a proprietary task, with best-of-ten sampling that raises cost and latency — it tells you the ceiling of a heavily sampled model, not the typical single-call experience. Open​AI's own evaluations on public benchmarks include leading performance on BixBench and 6-of-11 wins over GPT-5.4 on LABBench2, with the same vendor-reported caveat. The hallucination-rate claim — 40% lower than general models via critical-thinking tuning — is Open​AI's own measurement and has not been independently reproduced.

What these figures do establish is that Rosalind was tuned specifically for the mechanics of biological research: cloning-protocol design, RNA-function prediction, target prioritization. That is precisely where Claude Opus 5 has no published evidence, because it was not built for it. The comparison therefore hinges on whether you are choosing a model for biology work specifically or for the full range of reasoning tasks.

Where Claude Opus 5 wins

Claude Opus 5's independent record is broad and deep: 50.7 on the Artificial Analysis Intelligence Index (#4 of 141), 78.0 AA Coding (#2 of 138), GPQA Diamond 93.2, Humanity's Last Exam 54.9, and 79.3 Long-Context Recall. It is A​nthropic's most capable model for end-to-end software engineering, code review and bug finding, and visual analysis, built to stay coherent across very long, multi-step agentic sessions with heavy tool use. For a team whose primary workload is software, analysis pipelines, or general enterprise reasoning, Opus 5 is the safer choice on evidence, and it is available to anyone with an API key today — no qualification review.

Where GPT-Rosalind wins

GPT-Rosalind's advantage is domain depth: its training and tuning target the 50 biological workflows O​penAI lists — evidence synthesis, sequence-to-function, experimental design, molecular candidate comparison. On the same price per token as Opus 5, it offers a model that has seen vastly more molecular biology, genomics, and chemistry-specific material, plus the Life Sciences plugin that gives it 50+ tools and databases out of the box. For a medicinal chemist or genomics researcher, that is the difference between a brilliant generalist and a domain specialist at the same token cost.

The routing question

There is a practical wrinkle in this matchup: GPT-Rosalind is not yet on any third-party routing platform. Access runs through O​penAI's trusted-access program directly. Claude Opus 5, by contrast, is available on OrcaRouter at list price — $5.00/$25.00 per 1M tokens, exactly the provider rate with 0% markup — through one API alongside 200+ other models, with automatic failover and the routing DSL for composing models. Teams that pass a qualification review and get a Rosalind key can still route around it with OrcaRouter for everything else, or use failover so that if Rosalind's long domain calls stall, the request lands on an available generalist instead. That is the honest division of labor: Rosalind for the biology question, a routing layer for the rest of the pipeline.

Which should you choose?

If your work is life-sciences research — target discovery, protein engineering, genomics, experimental planning — GPT-Rosalind is the only frontier model purpose-built for it, and at the same token price as a generalist it is the better bet on that specific job, once your organization clears the trusted-access qualification. If your work is anything else — and even in a biotech lab most of the token spend is still on code, data pipelines, and general reasoning — Claude Opus 5 has the independent benchmark record, the open API access, and the routing ecosystem. The specialist's edge is real but narrow; the generalist's coverage is broad and verifiable. For most teams, the answer is not either/or: keep Rosalind for the discovery questions it was trained on, and route the rest through a generalist like Claude Opus 5 — where one API, zero markup, and failover make running both practical.